Skip to main content
News

Maryland stem cell companies advance therapies for diabetes, depression

By January 8, 2012No Comments
File photo “It’s a close-knit environment,” Kenneth Carter says of the relationship between Noble Life Sciences and NexImmune in Gaithersburg.

File photo “It’s a close-knit environment,” Kenneth Carter says of the relationship between Noble Life Sciences and NexImmune in Gaithersburg.

Two Maryland biotechs announced inroads in their efforts to develop stem cell treatments for depression and diabetes.

Neuralstem has gotten the regulatory go-ahead to advance to phase 1b in its ongoing clinical trial of its stem cell treatment for major depressive disorder.

NSI-189 stimulates new neuron growth in the brain’s hippocampus, which may be involved in depression and other conditions, including Alzheimer’s disease and post-traumatic stress disorder, according to the Rockville biotech.

To read the full, original article click on this link: Gazette.Net: Maryland stem cell companies advance therapies for diabetes, depression

{iframe}http://www.gazette.net/article/20120106/NEWS/701069694&template=gazette{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.